IPP Bureau
Lupin and Scope sign agreement for commercialization of Optase in Mexico
By IPP Bureau - October 08, 2024
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Lupin acquires nine brands of Medical Nutritional Institute in South Africa
By IPP Bureau - October 06, 2024
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Calquence granted priority review in US for patients with untreated mantle cell lymphoma
By IPP Bureau - October 06, 2024
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
By IPP Bureau - October 06, 2024
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark
By IPP Bureau - October 06, 2024
he company will focus on production of any pharmaceutical and biotechnological products
AIIMS, New organises conference on ‘Advancing Oral Health in India’
By IPP Bureau - October 06, 2024
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Briefs: Aurobindo Pharma and Lupin
By IPP Bureau - October 06, 2024
USFDA completes PAI of Lupin’s biotech facility in Pune
Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
By IPP Bureau - October 05, 2024
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir
By IPP Bureau - October 04, 2024
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
By IPP Bureau - October 04, 2024
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
By IPP Bureau - October 04, 2024
This is used to treat central diabetes insipidus and bedwetting
Piramal Pharma releases Sustainability Report FY 2023-24
By IPP Bureau - October 04, 2024
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)
By IPP Bureau - October 04, 2024
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Lilly invests US$ 4.5 billion to create advanced research and manufacturing site
By IPP Bureau - October 04, 2024
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
SK pharmteco invests US$ 260 million to expand global small molecule, peptide production
By IPP Bureau - October 04, 2024
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
